244 related articles for article (PubMed ID: 25548092)
21. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
22. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
23. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.
Schuurhuis DH; Verdijk P; Schreibelt G; Aarntzen EH; Scharenborg N; de Boer A; van de Rakt MW; Kerkhoff M; Gerritsen MJ; Eijckeler F; Bonenkamp JJ; Blokx W; van Krieken JH; Boerman OC; Oyen WJ; Punt CJ; Figdor CG; Adema GJ; de Vries IJ
Cancer Res; 2009 Apr; 69(7):2927-34. PubMed ID: 19318559
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
Oshita C; Takikawa M; Kume A; Miyata H; Ashizawa T; Iizuka A; Kiyohara Y; Yoshikawa S; Tanosaki R; Yamazaki N; Yamamoto A; Takesako K; Yamaguchi K; Akiyama Y
Oncol Rep; 2012 Oct; 28(4):1131-8. PubMed ID: 22895835
[TBL] [Abstract][Full Text] [Related]
25. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma.
Hersey P; Halliday GM; Farrelly ML; DeSilva C; Lett M; Menzies SW
Cancer Immunol Immunother; 2008 Jul; 57(7):1039-51. PubMed ID: 18157724
[TBL] [Abstract][Full Text] [Related]
27. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
28. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
[TBL] [Abstract][Full Text] [Related]
29. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
30. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells.
Mackensen A; Herbst B; Chen JL; Köhler G; Noppen C; Herr W; Spagnoli GC; Cerundolo V; Lindemann A
Int J Cancer; 2000 May; 86(3):385-92. PubMed ID: 10760827
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
[TBL] [Abstract][Full Text] [Related]
32. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
Chodon T; Comin-Anduix B; Chmielowski B; Koya RC; Wu Z; Auerbach M; Ng C; Avramis E; Seja E; Villanueva A; McCannel TA; Ishiyama A; Czernin J; Radu CG; Wang X; Gjertson DW; Cochran AJ; Cornetta K; Wong DJ; Kaplan-Lefko P; Hamid O; Samlowski W; Cohen PA; Daniels GA; Mukherji B; Yang L; Zack JA; Kohn DB; Heath JR; Glaspy JA; Witte ON; Baltimore D; Economou JS; Ribas A
Clin Cancer Res; 2014 May; 20(9):2457-65. PubMed ID: 24634374
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
[TBL] [Abstract][Full Text] [Related]
34. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
[TBL] [Abstract][Full Text] [Related]
35. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
36. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.
Van Nuffel AM; Benteyn D; Wilgenhof S; Pierret L; Corthals J; Heirman C; van der Bruggen P; Coulie PG; Neyns B; Thielemans K; Bonehill A
Mol Ther; 2012 May; 20(5):1063-74. PubMed ID: 22371843
[TBL] [Abstract][Full Text] [Related]
39. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
[TBL] [Abstract][Full Text] [Related]
40. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.
Schuurhuis DH; Lesterhuis WJ; Kramer M; Looman MG; van Hout-Kuijer M; Schreibelt G; Boullart AC; Aarntzen EH; Benitez-Ribas D; Figdor CG; Punt CJ; de Vries IJ; Adema GJ
Cancer Immunol Immunother; 2009 Jul; 58(7):1109-15. PubMed ID: 19018531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]